The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Crizotinib for ROS1 Rearranged Lung Cancer: Targeted Therapy for Rare Oncogenic Driver

ALK/MET/ROS1 inhibitor as initial targeted therapy for ROS1 fusion-positive NSCLC with subsequent generation alternatives

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Crizotinib for ROS1 Rearranged Lung Cancer: Targeted Therapy for Rare Oncogenic Driver?

ROS1 (c-ros oncogene 1) fusions create constitutively active oncogenic kinases driving lung adenocarcinoma in 1-2% of cases.

CD74-ROS1 is most common fusion partner with multiple other partners including SLC34A2-ROS1, EZR-ROS1 occurring less frequently.

Crizotinib was first FDA-approved ROS1 inhibitor leveraging structural similarity between ROS1 and ALK kinase domains.

ROS1 testing performed through fluorescence in situ hybridization, immunohistochemistry or next-generation sequencing platforms.

Newer ROS1 inhibitors including entrectinib, lorlatinib and repotrectinib offer improved CNS activity and resistance mutation coverage.

Symptoms

Vision changes including light flashes, photopsia and blurry vision require ophthalmologic monitoring and patient counseling.
Edema, particularly periorbital and lower extremity, is common requiring monitoring and supportive care.
Gastrointestinal symptoms including nausea, vomiting, diarrhea and constipation are common requiring management.
Hepatotoxicity with transaminase elevation requires baseline and serial monitoring with dose modification.
Bradycardia and QTc prolongation require electrocardiogram monitoring at baseline and during treatment.

Risk Factors

Younger age and never-smoker status correlate with ROS1 fusion-positive lung adenocarcinoma prevalence.
Brain metastases are common in ROS1-positive disease with limited crizotinib CNS penetration potentially affecting outcomes.
Acquired resistance mutations including G2032R limit crizotinib durability requiring next-generation therapy options.
Concomitant strong CYP3A4 inhibitors and inducers require dose adjustments given metabolic considerations.
Pre-existing cardiac conditions affect bradycardia tolerability and QTc prolongation considerations.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed metastatic NSCLC adenocarcinoma should undergo molecular testing including ROS1 rearrangement analysis.
  • ROS1-positive disease progression on crizotinib warrants consideration of newer ROS1 inhibitors with rebiopsy for resistance assessment.
  • Brain metastasis development on crizotinib may benefit from CNS-active alternatives including lorlatinib or entrectinib.
  • Vision changes during treatment require ophthalmologic evaluation distinguishing crizotinib effects from other causes.
  • Significant cardiac symptoms, bradycardia or syncope require cardiac evaluation and treatment modification consideration.

Treatment Methods

01
Crizotinib 250 mg twice daily continuous dosing represents standard regimen for ROS1-positive NSCLC.
02
Alternative first-line agents including entrectinib 600 mg daily or repotrectinib offer improved CNS penetration.
03
Brain MRI surveillance every 3-6 months given CNS metastasis predilection and response evaluation.
04
Comprehensive monitoring including liver function, ECG, ophthalmologic assessment and edema evaluation supports safety.
05
Multidisciplinary care including medical oncology, neuro-oncology, ophthalmology when needed and supportive care optimizes outcomes through sequential targeted therapy strategies for this rare but actionable molecular subset of lung cancer.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.